About aflibercep t
Vascular endothelial growth factor inhibitor
Used for
- Treats neovascular age-related macular degeneration
- Treats diabetic macular edema and diabetic retinopathy
- Treats macular edema after retinal vein occlusion
- Treats retinopathy of prematurity
Usual adult dose
For age-related macular degeneration, diabetic macular edema, or retinal vein occlusion: 8 mg injected into the eye every 4 weeks for three doses, then usually every 8–16 weeks, depending on condition and response.
Usual dose in children
For retinopathy of prematurity: 0.4 mg injected into each affected eye; repeat doses may be given if needed.
Common side effects
- Eye redness, pain, or irritation
- Increased pressure inside the eye
- Floaters or blurred vision
- Rarely, severe eye infection or retinal detachment
Important warnings
- Given only by an eye specialist as an injection into the eye
- Seek urgent care for sudden vision loss, worsening pain, or marked redness
- May increase the risk of blood clots, heart attack, or stroke
- Do not use with an active or suspected eye infection
Pregnancy
Pregnancy safety is uncertain. Use is generally avoided during pregnancy unless the eye specialist judges treatment essential.
Breastfeeding
It is unknown whether aflibercept enters breast milk. Discuss treatment timing and breastfeeding with the treating specialist.
Interactions
- No major systemic drug interactions are established; tell the eye specialist about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.